Cognitive functions and elderly cancer patients receiving anticancer treatment: A prospective study

Toxicities and functional consequences of systemic chemotherapy in elderly Korean patients with cancer: A prospective cohort study using Comprehensive Geriatric Assessment

“…Neurocognitive decline after systemic chemotherapy is known to be a common phenomenon in cancer survivors. 23,24 Minisini et al described changes in the MMSE at baseline, and at 3 and 6 months after treatment in the patients treated with chemotherapy, 25 and reported no significant decline along a short time interval (6 months), which is not consistent with our findings. Hurria et al also reviewed the barriers to investigate whether chemotherapy-associated cognitive dysfunction existed in the elderly patients.…”

Hormone therapy in elderly breast cancer patients with comorbidities

“…Recently, Minisini et al [54] reported the results of a consecutive series of cancer outpatients ≥65 years old prospectively assessed by means of the neuropsychological Cambridge Cognitive Examination (CAMCOG) test. Patients were categorized in three groups (group 1, no anticancer treatment; group 2, receiving chemotherapy; group 3, receiving endocrine therapy).…”

An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors

“…An approach to address this issue is to utilize brief screening instruments such as Mini-Mental State Examination (MMSE) [36], Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [37], and High Sensitivity Cognitive Screen (HSCS) [38]. From the review, RBANS was employed in two studies [6,7] conducted by Jansen, while HSCS and MMSE were utilized in three studies [39][40][41] and five studies [40,[42][43][44][45], respectively.…”